Table of Contents
A University of Utah report, published in late October 2025, describes preliminary research into psilocybin as a possible intervention for depression among health care workers. Full methodology and outcome data were not available in the source text, so specific results cannot be reported here.
- An emerging research focus: Investigators at the University of Utah are actively studying psilocybin in a population, health care workers, that carries unusually high rates of occupational burnout and depression.
- Caution is warranted: Because the underlying study details were not accessible in the source, no specific effect sizes, sample sizes, or conclusions can be confirmed at this time.
- A growing area: Research into psilocybin-assisted approaches for depression has expanded significantly in recent years, and trials targeting specific occupational groups represent a newer direction in that work.
- Watch this space: When the full study or peer-reviewed report becomes available, it will allow a more complete evaluation of what these findings actually show.
- Model
- human (reported)
- Sample
- Not confirmed from available source text
- Dose
- Not confirmed from available source text
- Design
- Not confirmed from available source text
- Key outcome
- Depression symptoms in health care workers (reported; specifics unavailable)
- Main limitation
- Source page was blocked by a security wall; only the headline was retrievable
What the Research Examined
The University of Utah published a report on or around October 28, 2025, under the headline ‘Psilocybin shows promise for health care worker depression.’ The piece appears to describe a clinical investigation into psilocybin as a possible tool for addressing depression in health care professionals, a group that has faced elevated rates of burnout and mental health difficulty, particularly since the COVID-19 pandemic. Beyond the headline and outlet name, the page content was not retrievable because the university’s website returned a security verification block during access.
Because the underlying text was inaccessible, no specific study design, participant count, dosing protocol, or outcome data can be reported here with confidence. Fabricating those details would violate our commitment to accuracy, so this entry acknowledges the gap openly. If you are following the broader arc of psilocybin research and its clinical applications, this announcement is worth tracking once the full report or linked peer-reviewed study becomes available through PubMed or the journal of record.
Health care workers as a specific study population represent a meaningful direction in psilocybin research. General-population depression trials have produced encouraging early results in several institutions, and extending that inquiry to an occupationally stressed group carries both scientific and public-health rationale. We will update this entry when the primary source is accessible.
What the Findings Show
- Outcome data.Specific numerical findings were not retrievable from the source. The headline indicates a positive signal for depression, but effect sizes, response rates, and statistical results cannot be confirmed.
- Population.The reported study targets health care workers, a population noted for high occupational stress and elevated depression prevalence, though sample size and inclusion criteria are unconfirmed.
This entry will remain intentionally sparse on numbers until the primary study text or a peer-reviewed publication is accessible. Reporting invented statistics, even plausible-sounding ones, would be a disservice to readers making decisions about their health or about the credibility of this research area.
Does psilocybin help with depression in health care workers?
Early research from the University of Utah appears to suggest a positive signal, but the study details, including design, sample size, and specific outcomes, were not available in the source reviewed here. No firm conclusions can be drawn until the full study is accessible.
What This Is, and What It Is Not
This is This entry is based solely on a press-release headline; the full source page was blocked and no underlying study text was retrieved.
This is not This is not a summary of a peer-reviewed study, and it does not establish that psilocybin treats or cures depression in any population. Nothing here constitutes medical advice, and readers should consult a qualified clinician before drawing personal conclusions.
Our Take
Within our community, the idea of extending sacramental inquiry toward those who carry the weight of caring for others carries its own resonance. Health care workers spend their vocational lives at the threshold between suffering and relief. That a research institution is now asking whether psilocybin might offer some restoration to that group feels consistent with what many in contemplative and psychedelic traditions have long understood: that the healer also needs tending. We hold this early signal with hope and with discipline, waiting for the full evidence before saying more than the data allow.
If this line of research speaks to you, whether you work in health care yourself, love someone who does, or simply follow the science with genuine curiosity, we welcome you to stay close to this work as it develops. The Mycelium Report exists precisely for moments like this: a headline worth watching, a question worth sitting with, a direction that may matter. Ground yourself in what is known, hold space for what is still unfolding, and return here when the fuller picture arrives.
Frequently Asked Questions
What did the University of Utah find about psilocybin and health care worker depression?
The university announced early research suggesting psilocybin may help with depression in health care workers, but the full study text was not available for review. Specific findings, sample sizes, and outcome data cannot be confirmed from the headline alone.
Is psilocybin approved to treat depression in health care workers?
No. Psilocybin remains a Schedule I controlled substance in the United States and is not approved by the FDA to treat depression in any population. The University of Utah work appears to be investigational research, not a basis for clinical use.
Why are health care workers being studied in psilocybin depression trials?
Health care workers experience some of the highest rates of occupational burnout and depression of any professional group. Researchers are increasingly examining whether psilocybin-assisted approaches might address treatment-resistant or occupationally driven depression in this population.
Where can I read the full University of Utah psilocybin study?
The original press release was published at attheu.utah.edu, though the page was not accessible at time of writing. Searching PubMed or the university’s research portal for the lead investigators may surface the underlying peer-reviewed paper once published.
Should I consider psilocybin for my own depression based on this report?
No. This is early, unconfirmed research reported from a single headline. It does not constitute medical advice. Anyone considering treatment for depression should speak with a licensed mental health or medical professional about evidence-based options currently available to them.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
